Aviso Wealth Management Trims Position in Stryker Co. (NYSE:SYK)

Aviso Wealth Management decreased its holdings in Stryker Co. (NYSE:SYK) by 6.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 950 shares of the medical technology company’s stock after selling 70 shares during the quarter. Aviso Wealth Management’s holdings in Stryker were worth $342,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in SYK. Swedbank AB boosted its holdings in shares of Stryker by 10.9% during the 3rd quarter. Swedbank AB now owns 51,070 shares of the medical technology company’s stock valued at $18,450,000 after buying an additional 5,032 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Stryker during the third quarter worth about $317,000. Independent Advisor Alliance grew its holdings in Stryker by 4.8% in the third quarter. Independent Advisor Alliance now owns 6,824 shares of the medical technology company’s stock worth $2,465,000 after purchasing an additional 312 shares during the period. Brown Brothers Harriman & Co. increased its stake in shares of Stryker by 34.6% during the third quarter. Brown Brothers Harriman & Co. now owns 7,433 shares of the medical technology company’s stock valued at $2,685,000 after purchasing an additional 1,912 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Stryker by 3.9% during the third quarter. The Manufacturers Life Insurance Company now owns 1,257,091 shares of the medical technology company’s stock valued at $454,136,000 after purchasing an additional 47,322 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now directly owns 14,895 shares of the company’s stock, valued at $5,705,827.65. This represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on SYK. Royal Bank of Canada raised their price objective on Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research report on Wednesday, January 29th. Needham & Company LLC reiterated a “buy” rating and issued a $442.00 price target on shares of Stryker in a research note on Friday, March 21st. JMP Securities restated a “market perform” rating on shares of Stryker in a research note on Tuesday, February 18th. Truist Financial upped their target price on shares of Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research note on Thursday, January 30th. Finally, Citigroup reissued a “buy” rating and set a $450.00 price target on shares of Stryker in a research report on Wednesday, February 26th. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $421.90.

Stryker Stock Down 0.3 %

Shares of NYSE SYK opened at $373.00 on Wednesday. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The firm’s 50-day moving average price is $384.76 and its 200-day moving average price is $374.34. The stock has a market capitalization of $142.33 billion, a price-to-earnings ratio of 48.07, a P/E/G ratio of 2.93 and a beta of 0.95.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the prior year, the company posted $3.46 EPS. On average, equities research analysts anticipate that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.90%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio is currently 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.